We are pleased to announce that the International Society of Atopic Dermatitis (ISAD) has been awarded a Research Networking Grant from the LEO Foundation to support the international scientific networking and consolidation workshop for Treat-to-Target in Atopic Dermatitis (T2T-AD) at the Rajka Symposium 2027 in Augsburg, Germany, building on preparatory steps initiated at Rajka Melbourne 2025 and continuing at […]
Read More
Announcement If your submission has been selected for an oral presentation (in a plenary session or during a booth session), your travel grant is hereby awarded if you applied before the deadline. Please check if the reference of your abstract (#2—) is displayed in the program (plenary or booth sessions). For International applicants: Accommodation at […]
Read More
Periostin in atopic dermatitis: the “Purloined Letter” hiding in plain sight? Twenty years after linking periostin to IL-4/IL-13–driven airway remodeling in asthma [1], Izuhara and colleagues revisit a story they helped initiate [2]. The situation recalls Edgar Allan Poe’s The Purloined Letter, in which the object everyone is searching for escapes detection precisely because it […]
Read MoreAnnouncement If your submission has been selected for an oral presentation (in a plenary session or during a booth session), your travel grant is hereby awarded. Please check if the reference of your abstract (#2—) is displayed in the program. For International delegates: Accommodation at the China World Hotel is now included in the grant! […]
Read More
When “Severe AD” Is Not Just AD: Eczema as the First Sign of Inborn Errors of ImmunityAubert H et al. British Journal of Dermatology. 2026.➜ DOI: 10.1093/bjd/ljag308Why it matters:Among 373 patients with genetically defined inborn errors of immunity with atopy (IEIs-A), eczema affected 50.9%, often beginning in infancy and sometimes years before severe or unusual infections. [...] Read More
Effective care for atopic dermatitis (AD) should not be a privilege. Everyone living with AD should have access to essential, safe and affordable treatment, from basic skin care and moisturizers to the medicines required for adequate disease control. The recent inclusion of low-cost emollients for AD in the WHO Essential Medicines List is an important […]
Read More
In conjunction with the World Atopic Eczema Day, the Asian Society of Pediatric Dermatology (ASPD) is organizing the annual ASPD Eczema Education Week 2026, with an exciting lineup of programmes and activities for both Healthcare Professionals and the public across Asia! The highly anticipated Public Forum “Truth vs Myth: Understanding Childhood Eczema” aims to provide a platform […]
Read More
#TSW The MEDIATE Initiative (Mitigating Eczema Disinformation and Intervening with AI Technology Education) is a project focused on developing an autonomous digital intervention for self-diagnosed Topical Steroid Withdrawal (TSW). The Clinical Challenge The dermatological community is increasingly facing the consequences of poor treatment adherence aggravated by “corticophobia”. This challenge has been exacerbated over the past […]
Read More
Standardizing the approach without standardizing the patient The rapid expansion of effective systemic treatments has made Treat-to-Target a natural next step in atopic dermatitis. Once substantial improvement becomes achievable for many patients, it is no longer sufficient to ask whether a treatment works. We must determine what level of control should be reached, when it […]
Read More
Eczema herpeticum after topical JAK inhibition:Eczema Herpeticum Following Topical Ruxolitinib Use: A Report of Two CasesZhang K et al. Annals of Allergy, Asthma & Immunology. 2026.➜ DOI: 10.1016/j.anai.2026.06.016Why it matters:Eczema herpeticum is one of the most clinically important infectious complications of AD. These two cases are noteworthy because they occurred following treatment with topical ruxolitinib, reminding [...] Read More